share_log

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

基准重申对Anebulo Pharmicals的投机性买盘,维持8美元的目标股价
Benzinga ·  2023/10/03 11:52

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.

基准分析师罗伯特·沃瑟曼重申安尼尔制药(纳斯达克:ANEB)的投机性买入,并维持8美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发